C2N Diagnostics

0

Developing and commercializing novel diagnostics for Alzheimer’s disease and related forms of neurodegeneration to improve treatment decisions and patients’ lives

• State-of-the-art proprietary liquid-chromatography-tandem mass spectrometry (LC-MS/MS) methodologies

• Blood tests to assess for brain amyloid pathology - The PrecivityAD® and PrecivityAD2™ tests

• Extensive domain expertise; leading neurological scientists and researchers on staff

Click on the video to learn more about the history of C2N Diagnostics and development of the Precivity™ blood tests for Alzheimer’s disease.

C2N’s Precivity™ tests are innovative new blood tests for Alzheimer’s disease

Visit Site

C2N is a specialty diagnostics company providing exceptional laboratory services and products in the field of brain health. C2N’s high-resolution mass spectrometry-based biomarker products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiological studies to improve global public health.

C2N’s Precivity™ tests are innovative new blood test intended for use in patients with cognitive impairment. These tests aim to help health care professionals determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease, and aid in medical management and treatment decisions.

The PrecivityAD2™ blood test is intended for use in patients aged 50 and older with signs or symptoms of mild cognitive impairment or dementia who are undergoing evaluation of Alzheimer’s disease or dementia.

The PrecivityAD® blood test is intended for use in patients aged 55 and old with signs or symptoms of mild cognitive impairment or dementia who are undergoing evaluation of Alzheimer’s disease or dementia.

The Precivity-ApoE™ blood test is indicated for use in adult patients for whom knowledge of apolipoprotein E2,E3,E4 allele status may be informative for medical management and treatment decisions.

Only a health care professional can order the Precivity™ tests.

The test is available in all 50 states and the District of Columbia.

News

Nov 24, 2025 C2N Diagnostics Awarded Rigorous New York State Department of Health Permit, Expanding Ability to Provide Its Blood Tests toHelp Diagnose Alzheimer’s Disease Nov 24, 2025 Nov 24, 2025 Nov 13, 2025 C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization Nov 13, 2025 Nov 13, 2025 Oct 1, 2025 C2N Submits U.S. FDA Regulatory Filing for Its Alzheimer’s Disease Blood Test Oct 1, 2025 Oct 1, 2025

Media Coverage

Nov 26, 2025 360Dx: C2N Diagnostics Receives Lab Permit from NY State Nov 26, 2025 Nov 26, 2025 Sep 4, 2025 St. Louis Magazine: C2N’s expansion into former Goodwill building boosts St. Louis’ bioscience startup ecosystem Sep 4, 2025 Sep 4, 2025 Aug 8, 2025 Patient Care: Novel Plasma Assay That Selectively Detect Tau Characteristics Will Refine Clinical Study of Alzheimer’s Disease Aug 8, 2025 Aug 8, 2025

Webinars

Sep 6, 2024 A New Paradigm in the Detection of Amyloid Pathology: The Emergence of Highly Accurate Blood Tests to Enhance the Diagnostic Odyssey for Patients with Cognitive Impairment Sep 6, 2024 Sep 6, 2024 May 7, 2024 Clinical Use of Blood Biomarkers in the Era of Disease Modifying Treatments for Early Symptomatic Alzheimer’s Disease May 7, 2024 May 7, 2024 Oct 3, 2023 Goldman Sachs Alzheimer’s Disease Day — Infrastructure considerations: Outlook for blood-based testing Oct 3, 2023 Oct 3, 2023

Subscribe to our newsletter.

Sign up with your email address to receive news and updates.

Email Address Sign Up Thank you!